VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3 Study met primary endpoint of statistically significant weight ...
Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...
Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results